Literature DB >> 28659618

An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.

A Lollies1, S Hartmann2, M Schneider1,2, T Bracht3, A L Weiß1, J Arnolds4, L Klein-Hitpass1, B Sitek3, M-L Hansmann2, R Küppers1, M A Weniger1.   

Abstract

Classical Hodgkin lymphoma (cHL) and anaplastic large cell lymphoma (ALCL) feature high expression of activator protein-1 (AP-1) transcription factors, which regulate various physiological processes but also promote lymphomagenesis. The AP-1 factor basic leucine zipper transcription factor, ATF-like 3 (BATF3), is highly transcribed in cHL and ALCL; however, its functional importance in lymphomagenesis is unknown. Here we show that proto-typical CD30+ lymphomas, namely cHL (21/30) and primary mediastinal B-cell lymphoma (8/9), but also CD30+ diffuse large B-cell lymphoma (15/20) frequently express BATF3 protein. Mass spectrometry and co-immunoprecipitation established interactions of BATF3 with JUN and JUNB in cHL and ALCL lines. BATF3 knockdown using short hairpin RNAs was toxic for cHL and ALCL lines, reducing their proliferation and survival. We identified MYC as a critical BATF3 target and confirmed binding of BATF3 to the MYC promoter. JAK/STAT signaling regulated BATF3 expression, as chemical JAK2 inhibition reduced and interleukin 13 stimulation induced BATF3 expression in cHL lines. Chromatin immunoprecipitation substantiated a direct regulation of BATF3 by STAT proteins in cHL and ALCL lines. In conclusion, we identified STAT-mediated BATF3 expression that is essential for lymphoma cell survival and promoted MYC activity in cHL and ALCL, hence we recognized a new oncogenic axis in these lymphomas.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28659618     DOI: 10.1038/leu.2017.203

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  58 in total

1.  Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.

Authors:  S Joos; M Küpper; S Ohl; F von Bonin; G Mechtersheimer; M Bentz; P Marynen; P Möller; M Pfreundschuh; L Trümper; P Lichter
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

2.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

3.  A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis.

Authors:  Kristoffer Weber; Udo Bartsch; Carol Stocking; Boris Fehse
Journal:  Mol Ther       Date:  2008-02-12       Impact factor: 11.454

4.  The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.

Authors:  Vassilis Atsaves; Lazaros Lekakis; Elias Drakos; Vasiliki Leventaki; Mehran Ghaderi; George E Baltatzis; Dimitris Chioureas; Dan Jones; Marianna Feretzaki; Chryssoula Liakou; Panayiotis Panayiotidis; Vassilis Gorgoulis; Efstratios Patsouris; L Jeffrey Medeiros; Francois X Claret; George Z Rassidakis
Journal:  Br J Haematol       Date:  2014-08-22       Impact factor: 6.998

Review 5.  The biology and management of systemic anaplastic large cell lymphoma.

Authors:  Greg Hapgood; Kerry J Savage
Journal:  Blood       Date:  2015-04-13       Impact factor: 22.113

6.  c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.

Authors:  Elias Drakos; Vasiliki Leventaki; Ellen J Schlette; Dan Jones; Pei Lin; L Jeffrey Medeiros; George Z Rassidakis
Journal:  Am J Surg Pathol       Date:  2007-03       Impact factor: 6.394

7.  Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.

Authors:  S Eckerle; V Brune; C Döring; E Tiacci; V Bohle; C Sundström; R Kodet; M Paulli; B Falini; W Klapper; A B Chaubert; K Willenbrock; D Metzler; A Bräuninger; R Küppers; M-L Hansmann
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

8.  Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.

Authors:  Enrico Tiacci; Claudia Döring; Verena Brune; Carel J M van Noesel; Wolfram Klapper; Gunhild Mechtersheimer; Brunangelo Falini; Ralf Küppers; Martin-Leo Hansmann
Journal:  Blood       Date:  2012-09-05       Impact factor: 22.113

9.  Overexpression of Batf induces an apoptotic defect and an associated lymphoproliferative disorder in mice.

Authors:  M R Logan; K L Jordan-Williams; S Poston; J Liao; E J Taparowsky
Journal:  Cell Death Dis       Date:  2012-05-17       Impact factor: 8.469

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more
  20 in total

1.  Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells.

Authors:  Marc A Weniger; Enrico Tiacci; Stefanie Schneider; Judith Arnolds; Sabrina Rüschenbaum; Janine Duppach; Marc Seifert; Claudia Döring; Martin-Leo Hansmann; Ralf Küppers
Journal:  J Clin Invest       Date:  2018-06-11       Impact factor: 14.808

2.  Cutting Edge: Batf3 Expression by CD8 T Cells Critically Regulates the Development of Memory Populations.

Authors:  Zhijuan Qiu; Camille Khairallah; Galina Romanov; Brian S Sheridan
Journal:  J Immunol       Date:  2020-07-15       Impact factor: 5.422

Review 3.  Hodgkin lymphoma.

Authors:  Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett
Journal:  Nat Rev Dis Primers       Date:  2020-07-23       Impact factor: 52.329

Review 4.  An Update on the Pathology and Molecular Features of Hodgkin Lymphoma.

Authors:  Akira Satou; Taishi Takahara; Shigeo Nakamura
Journal:  Cancers (Basel)       Date:  2022-05-26       Impact factor: 6.575

5.  Intestinal epithelium-derived BATF3 promotes colitis-associated colon cancer through facilitating CXCL5-mediated neutrophils recruitment.

Authors:  Y Lin; L Cheng; Y Liu; Y Wang; Q Wang; H L Wang; G Shi; J S Li; Q N Wang; Q M Yang; S Chen; X L Su; Y Yang; M Jiang; X Hu; P Fan; C Fang; Z G Zhou; L Dai; H X Deng
Journal:  Mucosal Immunol       Date:  2020-05-28       Impact factor: 7.313

6.  S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells.

Authors:  K Vrzalikova; M Ibrahim; M Vockerodt; T Perry; S Margielewska; L Lupino; E Nagy; E Soilleux; D Liebelt; R Hollows; A Last; G Reynolds; M Abdullah; H Curley; M Care; D Krappmann; R Tooze; J Allegood; S Spiegel; W Wei; C B J Woodman; P G Murray
Journal:  Leukemia       Date:  2017-09-07       Impact factor: 11.528

7.  MiR-760 suppresses human colorectal cancer growth by targeting BATF3/AP-1/cyclinD1 signaling.

Authors:  Ling Cao; Yulin Liu; Dan Wang; Lan Huang; Feng Li; Jinbo Liu; Chaoqi Zhang; Zhibo Shen; Qun Gao; Weitang Yuan; Yi Zhang
Journal:  J Exp Clin Cancer Res       Date:  2018-04-16

8.  IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.

Authors:  Cecilia Bandini; Aldi Pupuleku; Elisa Spaccarotella; Elisa Pellegrino; Rui Wang; Nicoletta Vitale; Carlotta Duval; Daniela Cantarella; Andrea Rinaldi; Paolo Provero; Ferdinando Di Cunto; Enzo Medico; Francesco Bertoni; Giorgio Inghirami; Roberto Piva
Journal:  Cancers (Basel)       Date:  2018-01-18       Impact factor: 6.639

Review 9.  New developments in the pathology of malignant lymphoma: a review of the literature published from May to August 2017.

Authors:  J H van Krieken
Journal:  J Hematop       Date:  2017-09-30       Impact factor: 0.196

Review 10.  The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL).

Authors:  Ivonne A Montes-Mojarro; Julia Steinhilber; Irina Bonzheim; Leticia Quintanilla-Martinez; Falko Fend
Journal:  Cancers (Basel)       Date:  2018-04-04       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.